| General Information | |
|---|---|
| ZINC ID | ZINC000071329493 |
| Molecular Weight (Da) | 336 |
| SMILES | O=C(c1ccccc1)N1CC[C@](O)(c2ccccn2)[C@H]2CCCC[C@@H]21 |
| Molecular Formula | C21N2O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 96.287 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 25 |
| LogP | 2.829 |
| Activity (Ki) in nM | 1348.963 |
| Polar Surface Area (PSA) | 53.43 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | - |
| Androgen receptor binding | - |
| Plasma protein binding | 0.74425876 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.43 |
| Ilogp | 3.68 |
| Xlogp3 | 2.86 |
| Wlogp | 2.88 |
| Mlogp | 2.55 |
| Silicos-it log p | 3.02 |
| Consensus log p | 3 |
| Esol log s | -3.88 |
| Esol solubility (mg/ml) | 4.39E-02 |
| Esol solubility (mol/l) | 1.30E-04 |
| Esol class | Soluble |
| Ali log s | -3.64 |
| Ali solubility (mg/ml) | 7.69E-02 |
| Ali solubility (mol/l) | 2.29E-04 |
| Ali class | Soluble |
| Silicos-it logsw | -5.25 |
| Silicos-it solubility (mg/ml) | 1.91E-03 |
| Silicos-it solubility (mol/l) | 5.68E-06 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.32 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 0 |
| Synthetic accessibility | 3.4 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.74 |
| Logd | 2.727 |
| Logp | 2.662 |
| F (20%) | 0.648 |
| F (30%) | 0.008 |
| Mdck | 1.83E-05 |
| Ppb | 0.8605 |
| Vdss | 1.334 |
| Fu | 0.0678 |
| Cyp1a2-inh | 0.111 |
| Cyp1a2-sub | 0.487 |
| Cyp2c19-inh | 0.8 |
| Cyp2c19-sub | 0.277 |
| Cl | 1.979 |
| T12 | 0.344 |
| H-ht | 0.475 |
| Dili | 0.615 |
| Roa | 0.065 |
| Fdamdd | 0.231 |
| Skinsen | 0.856 |
| Ec | 0.004 |
| Ei | 0.22 |
| Respiratory | 0.944 |
| Bcf | 0.445 |
| Igc50 | 3.415 |
| Lc50 | 3.512 |
| Lc50dm | 4.06 |
| Nr-ar | 0.268 |
| Nr-ar-lbd | 0.059 |
| Nr-ahr | 0.069 |
| Nr-aromatase | 0.613 |
| Nr-er | 0.27 |
| Nr-er-lbd | 0.01 |
| Nr-ppar-gamma | 0.003 |
| Sr-are | 0.203 |
| Sr-atad5 | 0.022 |
| Sr-hse | 0.031 |
| Sr-mmp | 0.469 |
| Sr-p53 | 0.027 |
| Vol | 358.665 |
| Dense | 0.937 |
| Flex | 24 |
| Nstereo | 0.125 |
| Nongenotoxic carcinogenicity | 3 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 0 |
| Synth | 0.915 |
| Fsp3 | 3.271 |
| Mce-18 | 0.429 |
| Natural product-likeness | 75.6 |
| Alarm nmr | -0.312 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Accepted |